You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Written by a leading researcher in immunology, ImmunoPharmaceuticals specifically focuses on immunologically active drugs recently tested for clinical activity or recently approved for medical use. Each chapter focuses on a single drug or class of drugs and discusses data from basic and preclinical research concerning mechanisms of action. Preclinical models are compared with clinical findings to allow the reader to evaluate the predictive value of those models. Featured drugs are being studied for therapy of cancer, arthritic disease, autoimmune disease, immunodeficiency disease, transplantation, and determination of sepsis. Overviews of the retinoids in cancer therapy and preclinical studies on flavonoids are featured.
Drug delivery technologies represent a vast and vital area of Research and Development. The demand for innovative drug delivery systems continues to grow, and this growth continues to drive new developments. Building on the foundation provided by the first edition, Drug Delivery Systems, Second Edition covers the latest developments in both
Drugs of Abuse and Addiction: Neurobehavioral Toxicology examines drugs of abuse and addiction and how they affect behavior. This book considers the entire range of addiction research in humans and animals, using a multidisciplinary approach to discuss all areas of the neuro- and behavioral sciences involved. Emphasis is on acute and chronic effect
This is the first book to describe the pharmacological interaction of drugs and exercise with organ systems at molecular and cellular levels. It explains the effect of exercise on pharmacokinetics and pharmacodynamics of drugs, and the activation or induction of antioxidant enzymes which may take place via the adenosine receptor or may occur due to gene expression.
Poly (ADP-ribose) polymerase (PARP), also termed poly (ADP-ribose) synthetase (PARS) is a nuclear enzyme with a wide range of functions, including regulation of DNA repair, cell differentiation, and gene expression. More than a decade after the identification of PARP-like enzymatic activities in mammalian cells, a novel role was proposed for this e
Recent research in cell death mechanisms has rekindled interest in PARP's (Poly (ADP-Ribose) Polymerase) intriguing role in necrosis and apoptosis. While the details of how PARP1 functions are still being elucidated, it has tremendous potential as a promising drug target. PARP inhibitors' dual actions of preventing cell death and abating inflammati
Osteoporosis, a growing epidemic among women in North America, Europe, and Japan, is a painful, costly disease that has presented a treatment challenge to healthcare professionals. Until recently, therapies have focused on agents that slow bone resorption, and have had only limited success at increasing bone mass.
The theoretical and practical significance of antimuscarinic drugs is more obvious today than ever before. Antimuscarinics have helped to explore the pathomechanisms of of Alzheimer's disease, and to treat the symptoms of Parkinson's, cardiovascular problems, gastrointestinal diseases, and even nerve gas poisoning. No other drug class can claim as long a history with so many therapeutic applications, yet the most significant developments in this broad chapter of pharmacology come from the discovery of different muscarinic receptor sites in the peripheral and central nervous system and from the availability of many new selective agents, notably antagonists, for these different receptor types. Pharmacology of Antimuscarinic Agents, written by an expert in anesthesiology and drug research, focuses on the basic principles of antimuscarinic drugs, their therapeutic value, how they work, and what versions are now available in the U.S. and abroad. This is the first time in decades an author has reviewed historical and current literature to present a comprehensive, standard reference on the antimuscarinic family.
This substantially updated edition presents fundamental principles and concepts behind the various types of toxicological studies, and explains how to design and conduct studies and interpret results. The text explains the increasing need to monitor, assess, and reevaluate the toxicity database of many agents and evaluates the place of individual studies in the overall toxicological assessment of a chemical. Concise descriptions of the formats of in vivo and in vitro studies and methods used in assessing endpoints of toxicity make this an essential introduction and guide for anyone who needs to understand or conduct toxicological studies. Reflecting increasing interest in the "Three Rs" (Reducing, Refining, and Replacement of existing animal tests) in recent years, the Second Edition includes much more information on a variety of new alternative testing protocols. Particular attention is given to the new in vitro alternative testing procedures being incorporated into EEC regulations. The text also covers studies required by regulatory agencies around the world.
Published in 1997: Antibody Therapeutics is a comprehensive evaluation of progress toward using humanized antibodies as a new generation of therapeutics. The humanized antibodies that have led the way in product approval are discussed as case studies, offering an insight into the preclinical and clinical data acquired during the regulatory approval process. Leading experts offer their findings as examples of what works and what does not, saving you time and making your research more cost effective. This book is essential reading for researchers, clinicians, development and regulatory staff in pharmaceutical and biotechnology companies, and hospital staff, including policy and decision makers. It also provides postgraduate and medical students with an authoritative overview of the field.